### Guideline Page and Request

**BINV-Q (2 of 7)**

**Internal request:**

In response to the FDA approval of tucatinib + trastuzumab + capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more lines of prior HER2-targeted therapy in the metastatic setting, the panel voted on the addition of tucatinib + trastuzumab + capecitabine for this indication.

**External request:**

Submission from Seattle Genetics to consider the inclusion of tucatinib in combination with trastuzumab and capecitabine in the NCCN Breast Cancer Guidelines as a preferred therapy with a category 1 level of evidence for patients with HER2+ metastatic breast cancer (MBC), including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. This request is supported by the overall survival (OS) benefit observed in the HER2CLIMB trial. Additionally, consider inclusion, as a note, of the benefit that extended to those patients with previously untreated, treated stable, and/or treated progressing brain metastases.

### Panel Discussion/References

Based on a review of data and the recent FDA approval, the panel consensus was to include tucatinib + trastuzumab + capecitabine as a systemic treatment option for recurrent or stage IV (M1) HER2-positive breast cancer. This is a category 1, other recommended regimen.

The following footnote has been included: For adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more lines of prior HER2-targeted therapy in the metastatic setting.

**Reference:**


### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>1</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>